EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer

Parveen Kumar Goyal, Kavita Sangwan

Current Treatment Options in Oncology · 2024-11 · 25 (11) · 1337-1344

DOI: 10.1007/s11864-024-01268-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 11.10.2024. Verfasst von Parveen Kumar Goyal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Panipat Institute of Engineering &Technology (PIET) Samalkha, Panipat, Haryana, 132102, India. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Lung cancer is expected to contribute to about 0.234 million new cases and about 0.125 million mortalities in the United States in the year 2024. Small cell lung cancer (SCLC), a neuroendocrine carcinoma, has lesser prevalence but is more aggressive at an extensive stage where the tumor is not only confined to hemithorax, mediastinum, and supraclavicular region but spread beyond the supraclavicular region. The prognosis of SCLC, irrespective of the limited or extensive stage, is very poor. Only a 5-10% overall survival rate in five years is expected and with extensive-stage SCLC, long-term disease-free survival is rare. In May 2024, the USFDA approved Tarlatamab-dlle, a DLL3 targeted bi-specific T-cell engager, for treating extensive-stage SCLC in adult patients, on or after platinum-based chemotherapy or on progression. Before the approval of Tarlatamab-dlle, only a few drugs, such as Atezolizumab and Durvalumab, received FDA approval for treating extensive-stage SCLC. It might be possible that Tarlatamab-dlle received accelerated FDA approval for extensive-stage SCLC, leaving some questions unanswered at this stage. This manuscript is focused on clinical, pre-clinical, and other pharmacological aspects of Tarlatamab-dlle for extensive-stage SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsNeoplasm StagingHumansTreatment OutcomeDisease ManagementAntineoplastic Combined Chemotherapy ProtocolsMolecular Targeted TherapyMembrane ProteinsIntracellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

Bi-specific T-cell engagerDLL3-targetedExtensive-stageSCLC (small cell lung cancer)Tarlatamab-dlle

Substanzen

DLL3 protein, humanMembrane ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, Panipat Institute of Engineering &Technology (PIET) Samalkha, Panipat, Haryana, 132102, India.
  • Department of Pharmacy, Panipat Institute of Engineering &Technology (PIET) Samalkha, Panipat, Haryana, 132102, India. sangwank436@gmail.com.

Zitieren

APA

Goyal, P. K., & Sangwan, K. (2024). Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer. Current Treatment Options in Oncology, 25(11), 1337-1344. https://doi.org/10.1007/s11864-024-01268-3

Vancouver

Goyal PK, Sangwan K. Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer. Current Treatment Options in Oncology. 2024;25(11):1337-1344. doi:10.1007/s11864-024-01268-3

BibTeX
@article{Goyal2024,
  author = {Goyal, Parveen Kumar and Sangwan, Kavita},
  title = {Tarlatamab-dlle: A New Hope for Patients with Extensive-Stage Small-Cell Lung Cancer},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {11},
  pages = {1337--1344},
  doi = {10.1007/s11864-024-01268-3}
}
Kostenlos starten →